WO2016114470A1 - Extrait de grenade permettant de soulager les symptômes de la ménopause chez la femme, contenant une teneur élevée d'acide ellagique - Google Patents

Extrait de grenade permettant de soulager les symptômes de la ménopause chez la femme, contenant une teneur élevée d'acide ellagique Download PDF

Info

Publication number
WO2016114470A1
WO2016114470A1 PCT/KR2015/009464 KR2015009464W WO2016114470A1 WO 2016114470 A1 WO2016114470 A1 WO 2016114470A1 KR 2015009464 W KR2015009464 W KR 2015009464W WO 2016114470 A1 WO2016114470 A1 WO 2016114470A1
Authority
WO
WIPO (PCT)
Prior art keywords
pomegranate
pomegranate extract
extract
menopausal symptoms
ellagic acid
Prior art date
Application number
PCT/KR2015/009464
Other languages
English (en)
Korean (ko)
Inventor
이해연
Original Assignee
주식회사 건강사랑
이해연
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/596,778 external-priority patent/US9839659B2/en
Application filed by 주식회사 건강사랑, 이해연 filed Critical 주식회사 건강사랑
Priority to JP2017537301A priority Critical patent/JP6694888B2/ja
Priority to EP15878114.6A priority patent/EP3246040B1/fr
Priority to CN201510702482.XA priority patent/CN106491667B/zh
Publication of WO2016114470A1 publication Critical patent/WO2016114470A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine

Definitions

  • the ovary is a major source of estrogen.
  • pituitary gonadotropins follicle stimulating hormone and luteinizing hormone
  • progesterone production is reduced, and the cycle becomes more irregular.
  • the follicles will not react and will not produce estrogens.
  • Reduced secretion of estrogen has a significant effect not only on the urogenital system of women, but also throughout the body, and menopausal symptoms due to hormonal decline before or after menstruation is stopped and menstruation disappears.
  • phytoestrogens which are phytoestrogens, as safer substitutes for synthetic estrogens used in hormone replacement therapy.
  • the phytoestrogens refer to nonsteroidal compounds present in plants that exert an estrogenous effect in the body of animals, and most of the grains, fruits, and vegetables known to be effective in anticancer activity and heart disease contain trace amounts of phytoestrogens. It is included.
  • the inventors of the present invention have developed a health functional food containing a pomegranate extract, characterized in that it comprises 0.8 to 1.8 mg / g of ellagic acid, which is registered on the patent No. 10-1272602 dated May 29, 2013 It has been.
  • the highest concentration of ellagic acid contained in the pomegranate extract developed above was only 1.8 mg / g, and there was a case of taking a large amount of pomegranate extract in anticipation of a marked improvement in female menopausal symptoms, in which case the pomegranate extract contained
  • the high intake of polyphenols caused problems (eg, increased heart rate).
  • the technical problem to be achieved by the present invention is to provide a pomegranate extract and a method for preparing the same, which is effective in improving female menopausal symptoms and can be administered to individuals sensitive to polyphenol components.
  • the present invention provides a pomegranate extract containing 1.8 to 3.2 mg of ellagic acid per g of the total weight of the pomegranate extract and a method for preparing the same.
  • the present invention provides a pomegranate extract with an improved effect of improving female menopausal symptoms, characterized in that the ellagic acid content per g of the total weight of the pomegranate extract is 2.4 mg-3.2 mg, more preferably 2.7 mg-3.2 mg.
  • the concentration of ellagic acid is less than 1.8 mg / g is a slight improvement of the menopausal symptoms, if the concentration exceeds 3.2 mg / g there is a risk of side effects such as liver function levels GOT and GPT is out of the normal range.
  • the present invention provides a pomegranate extract, which contains 1.8-3.2 mg of ellagic acid per g of gross weight of pomegranate extract and has a maximum total daily pomegranate extract of 15 ml or less (preferably 10 ml or less).
  • a pomegranate extract which contains 1.8-3.2 mg of ellagic acid per g of gross weight of pomegranate extract and has a maximum total daily pomegranate extract of 15 ml or less (preferably 10 ml or less).
  • Increasing the content of ellagic acid in the pomegranate extract may improve female menopausal symptoms, but if the pomegranate extract is simply concentrated to increase the content of ellagic acid in the pomegranate extract, the content of ellagic acid may be increased to a high concentration, but at the same time unique to natural products At the same time the content of components of polyphenols, in particular of polyphenols, is also increased, thereby limiting administration to the polyphenolic component-sensitive individuals.
  • the present invention comprises ellagic acid in a high content of 1.8-3.2 mg per g of the total weight of the pomegranate extract, the maximum total daily capacity of pomegranate extract 15 ml or less (preferably, 10 ml or less) )
  • a pomegranate extract that is sufficient for women's menopausal symptoms improvement while minimizing the content of polyphenols by taking small doses
  • the ellagic acid is 1.8 to 3.2 per g of the total weight of the pomegranate extract. It provides a dietary supplement for improving women's menopausal symptoms, including a pomegranate extract containing a high content of mg as an active ingredient.
  • menopausal symptoms are hot flashes, sweating, insomnia, nervousness, depression, dizziness, lack of concentration, joint pain, headache, palpitations, vaginal dryness, fatigue, excitement, insomnia, memory loss, anxiety, atherosclerosis Etc., but is not limited thereto.
  • polyphenol refers to a substance in which one of hydrogen in the benzene ring (C 6 H 6 ) is substituted with a hydroxy group (-OH) and a phenol having a substance having two or more hydroxyl groups. It has been reported to have a net function such as antioxidant function, but when ingested in excess, side effects occur, such as liver damage or kidney damage.
  • the polyphenol sensitivity means that the risk of developing side effects due to polyphenol intake is relatively higher than that of the average individual, which is based on the individual who is at risk of developing menopausal symptoms or appears.
  • the pomegranate extract according to the present invention exhibited a sufficient effect of improving menopausal symptoms while minimizing the polyphenol content.
  • the polyphenol content per g of the total weight of the pomegranate extract is 10 mg-14 mg, more preferably 10 mg-13 mg, most preferably 10 mg-12.5 mg.
  • Pomegranate (Punica granatum L.) is a native plant in southeastern Asia, northwestern India and California, USA, and is now widely distributed in subtropical and tropical regions. Pomegranate, especially red pomegranate, has been known as a tonic for a long time, and is known to have a particularly good effect on preventing hypertension and atherosclerosis. In addition, it contains a large amount of water-soluble sugars of 38 to 47%, and contains a variety of vitamins and minerals.
  • Pomegranate extract according to the present invention may be different depending on the production time and harvesting time of the pomegranate used, the ellagic acid content per g total weight of the final pomegranate extract is 1.8 mg-3.2 mg, preferably 2.4 mg-3.2 mg, more Pomegranate should preferably be used, which can be between 2.7 mg and 3.2 mg.
  • Turkish pomegranate American pomegranate or mixtures thereof may be used in the present invention, such as Vietnamese pomegranate varieties such as Hicaznar pomegranate cv., Cekirdeksiz VI pomegranate cv., Silifke Asisi pomegranate cv., Katirbasi pomegranate cv. Or Lefan pomegranate cv. Etc., but is not limited thereto.
  • a preferred pomegranate site for preparing the pomegranate extract according to the present invention is pomegranate pulp.
  • the content of ellagic acid was significantly different between the pomegranate extract and the commercially available products according to the present invention, and in particular, compared to the pomegranate extract disclosed in Korean Patent Registration No. 10-1272602.
  • Representative components of the pomegranate extract as well as the content of components such as polyphenol components were almost the same, but there was a big difference in the content of ellagic acid. Due to these differences, even a limited amount of pomegranate extract per day can be expected to exert an excellent effect on improving women's menopausal symptoms.
  • the content of polyphenols in the pomegranate extract according to the present invention was hardly different from the polyphenol content of the pomegranate extract disclosed in Korean Patent Registration No. 10-1272602, thus achieving an equivalent level of menopausal symptoms improvement effect.
  • Pomegranate extract according to the present invention can achieve the equivalent effect with a relatively small dose compared to the pomegranate extract disclosed in Korea Patent Registration No. 10-1272602, and as a result, the intake of polyphenols contained in the pomegranate extract It is presumed that it is possible to take polyphenol-sensitive individuals.
  • the present invention also provides a composition for improving menopausal symptoms comprising a pomegranate extract of 1.8 mg-3.2 mg of ellagic acid per g of the total weight of pomegranate extract according to the present invention, preferably polyphenol content per g of the total weight of pomegranate extract It provides a composition for improving menopausal symptoms, including 10 mg-14 mg of pomegranate extract, which is also possible to take polyphenol-sensitive individuals.
  • the reason why the ellagic acid content of the pomegranate extract according to the present invention is high is due to differences in pomegranate origin, the use of only flesh, and a specific manufacturing method described below (eg, pomegranate extract concentration, heating temperature and pressure).
  • the present invention is not limited to these matters.
  • it may further comprise a step of filtration between each step, for example, before the step of removing the shell and seeds, before the autoclaving step, before the step of treating the starch enzyme, before the concentration step, or after the concentration step
  • the process may further comprise the step of filtering in one or more steps.
  • the pomegranate pulp decomposed product is sequentially heated and pressurized at least two times by heating and pressing at 70-100 ° C. and 400-850 mbar, and then depressurizing at 40-80 ° C. and 100-350 mbar to heat and concentrate at least one time.
  • the method may further include filtering at any one or more of steps after step S1, before step S2, before step S3, before step S4, and after step S4.
  • the present invention provides an extract using only pomegranate pulp that does not contain pomegranate peel and fruit.
  • Pomegranate peels and seeds can have side effects, for example, certain alkaloids in pomegranate peels can degrade the body's function, affect the respiratory system and muscles, and when poisoned, seizures and cramps , Coma can occur.
  • side effects such as tongue swelling, which are allergic, may occur in some people when the extract of pomegranate fruit is taken.
  • Pomegranate pulp is sequentially sterilized and then cooled. Sterilization is preferably carried out quickly at 100-105 ° C. for 50-80 seconds, more preferably 55-70 seconds, and preferably cooled to 48-55 ° C.
  • the frozen pomegranate pulp is subjected to starch degrading enzyme treatment. Preferably it is performed at 48-55 degreeC for 10-60 minutes, More preferably, it can carry out at 48-55 degreeC for 20-40 minutes.
  • starchase is not particularly limited and various starchase enzymes known in the art may be used. For example, pectinase, proteinase, amylase, cellulase and the like may be used. Preferably pectinase can be used.
  • the pomegranate pulp decomposed product is sequentially heated and pressurized at least two times by heating and pressing at 70-100 ° C. and 400-850 mbar, and depressurizing at 40-80 ° C. and 100-350 mbar to heat-concentrate one or more times.
  • the pomegranate pulp decomposed product is sequentially heated and concentrated by heating and pressing, followed by heating and depressurizing by reducing the temperature.
  • it is heated and pressurized to heat concentration at least two times, more preferably at least three times, and to depressurize to at least one time, more preferably at least two times, and heat-concentrate at least three times in total.
  • Heating and heating by heating and pressurizing are carried out within the temperature range of 70-100 °C and the pressure 400-850 mbar.
  • the temperature and pressure are varied according to the heating concentration order (number of times). If it is to pressurize is not limited and may be included in the scope of the present invention.
  • primary heat concentration at 70-85 ° C. to 400-550 mbar, secondary heat concentration at 85-92 ° C. to 550-750 mbar, and third heat concentration at 92-100 ° C. at 750-850 mbar. have. More preferably, primary heat concentration from 78-82 ° C. to 450-500 mbar, secondary heat concentration from 85-90 ° C. to 600-650 mbar, and third heat concentration from 92-98 ° C. to 800-850 mbar. Can be.
  • the heating and concentration under reduced pressure is carried out in the temperature range of 40-80 °C and the pressure condition of 100-350 mbar, and the temperature and pressure are varied according to the heating concentration order (number of times), but the temperature is reduced and the pressure is maintained within the temperature and pressure range. If it is to reduce the pressure is not limited and may be included in the scope of the present invention.
  • a fourth heat concentration at 250-350 mbar at 60-80 ° C. and a fifth heat concentration at 100-250 mbar at 40-60 ° C. is possible. More preferably, it is possible to concentrate the fourth heat at 300-330 mbar at 65-72 ° C. and the fifth heat at 100-150 mbar at 45-55 ° C.
  • the present invention also contains 1.8-3.2 mg of ellagic acid per g of the total weight of the pomegranate extract according to the present invention, and the pomegranate extract has a maximum daily total dose of 15 ml or less (preferably 10 ml or less). It provides a composition for improving women's menopausal symptoms comprising the extract as an active ingredient.
  • the composition for improving women's menopausal symptoms according to the present invention may be utilized for various purposes, for example, it may be used as a pharmaceutical composition or health functional food.
  • the present invention is effective in the pomegranate extract, containing 1.8-3.2 mg of ellagic acid per g of the total weight of the pomegranate extract, the maximum total daily pomegranate extract is 15 ml or less (preferably, 10 ml or less)
  • a health functional food or pharmaceutical composition for improving female menopausal symptoms including as an ingredient.
  • the health functional food according to the present invention includes a high concentration of ellagic acid, but the content of natural ingredients, particularly the content of polyphenols, includes pomegranate extract containing the same amount to a small amount as compared to conventional pomegranate extract as an active ingredient. Therefore, even when the maximum daily dose of pomegranate extract is 15 ml or less (preferably 10 ml or less), it exhibits a significant superior female menopausal symptom-improving effect, and thus polyphenol-sensitive susceptible administration is also possible.
  • the pomegranate pulp extract according to the present invention in case of taking the pomegranate pulp extract according to the present invention 15ml per day even after taking the health indicators of the human body (for example, red blood cell count (RBC), blood urea nitrogen ( BUN) level, aspartate amino transferase (AST) level, alanine amino transferase (ALT) level, creatine level, glucose level, SG level, etc.) are all within the normal range, so menopausal symptoms safely without any adverse effects on the living body The effect of the improvement can be achieved.
  • the health indicators of the human body for example, red blood cell count (RBC), blood urea nitrogen ( BUN) level, aspartate amino transferase (AST) level, alanine amino transferase (ALT) level, creatine level, glucose level, SG level, etc.
  • the dietary supplement according to the present invention can be provided by separately filling a single dose in a separate container, and in a single dose 15 ml-1 ml of pomegranate extract, preferably 15 ml, 14 ml, 13 ml, 12 ml, 11 It may comprise a dose of any of ml, 10 ml, 5 ml, 4 ml, 3 ml, 2 ml or 1 ml.
  • the health functional food according to the present invention in addition to pomegranate extract, Earl, Cornus, Dermis, Ganoderma lucidum, Dermis, Cuttlefish, Angelica, Gardenia, Astragalus, Malt, Tanga, Vitamin C, Fructooligosaccharide, Stevioside, Purified water, Malto Dextrin and the like may be further included alone or in a mixture within the range that does not inhibit for the purposes of the present invention, other medicinal ingredients and / or additives that may be further included in the health functional food of the present invention is limited to the above examples It doesn't happen.
  • the health functional food according to the present invention may include thiamine (vitamin B1), riboflavin, ascorbic acid, niacin, and vitamin B6 as water-soluble vitamins, and myristic acid, palmitic acid, stearic acid, oleic acid as fatty acids.
  • the weak acid component may include glycolic acid and acetic acid, and as amino acids including eight essential amino acids of threonine, valine, methionine, isoleucine, leucine, phenylalanine, tryptophan, and lysine , Aspartic acid, serine, glutamic acid, proline, glycine, alanine, cysteine, tyrosine, histidine, arginine and the like.
  • the present invention provides a method for improving the female menopausal symptom improving effect of the pomegranate extract, preferably in the method of controlling the content of ellagic acid to 1.8-3.2 mg per g of the total weight of the pomegranate extract, more preferably Is to adjust the content of ellagic acid to 2.4 mg-3.2 mg, more preferably 2.7 mg-3.2 mg.
  • the content of polyphenol is adjusted to 10 mg-14 mg, more preferably 10 mg-13 mg, most preferably 10 mg-12.5 mg, per g of the total weight of pomegranate extract. .
  • pomegranate extract per day can be expected to improve women's menopausal symptoms, and therefore, polyphenol-sensitive individuals can be administered.
  • the content of ellagic acid in the pomegranate extract was measured using a high performance liquid chromatography method.
  • SP C18 UG 120 (4.6mm ⁇ 50mm, 5 ⁇ m) was used as a column, and the mobile phase was separated by a gradient method using a 6: 4 mixture of purified water, 0.85% phosphoric acid and methanol and pure methanol.
  • Ellagic acid was detected at a wavelength of 370 nm with a UV detector.
  • the average ellagic acid content in the pomegranate extract prepared according to Example 1 was found to be 1.8-3.2 mg / g.
  • ellagic acid content of three commercially available products, pomegranate extracts prepared according to Korean Patent Registration No. 10-1272602 and pomegranate extracts prepared in Example 1 were evaluated according to the method described above. The results are shown in Table 1. Six samples with different lot numbers for each product were purchased to evaluate the content of ellagic acid.
  • product A is a pomegranate extract product of Shadaab Co.
  • product B is a pomegranate extract product of Pashapour Trading Co.
  • product C is a pomegranate extract product of Noosh Iran Co.
  • No. 10-1272602 is a pomegranate extract prepared according to the manufacturing method described in Korean Patent Registration No. 10-1272602.
  • the dosage of pomegranate extract according to Korean Patent Registration No. 10-1272602 is about the dosage of the pomegranate extract of the present invention. It can be seen that twice.
  • the content of polyphenol in the pomegranate extract was calculated by quantifying the sample using a spectrophotometer by dissolving the sample in distilled water, ultrasonic extraction, and reacting with a coloring reagent.
  • test solution was prepared by weighing 100 mg of the pomegranate extract prepared according to Example 1 in a 100 mL volumetric flask, adding distilled water to the mark and dissolving it by sonication. Take 7.5 mL of distilled water into the test tube, and add 1 mL of the standard solution and the test solution to the above test tube, and add 0.5 mL of Folin-denis reagent and 1 mL of 35% sodium carbonate in order, and mix, and leave for 1 hour in the dark.
  • the absorbance was then measured at 760 nm using an UV / Visible Spectrophotometer.
  • the calibration curve of the standard was prepared by using the difference between the absorbance of each standard and the absorbance of each blank test, and the difference between the absorbance of the pomegranate extract prepared according to Example 1 and the blank test absorbance of the pomegranate extract prepared according to Example 1 was applied to the calibration curve to calculate the total polyphenol content in the sample.
  • the total polyphenol content of the pomegranate extract of the present invention was confirmed to be similar to the total polyphenol content of the pomegranate extract prepared according to Korean Patent No. 10-1272602.
  • the degree of improvement of female menopausal symptoms of pomegranate pulp extract containing high content ellagic acid according to the present invention was evaluated by the following method.
  • Subjects with or without cardiac menopausal disorder who have undergone or have undergone hormonal replacement therapy at least six months in advance, and who have amenorrhea after bilateral ovarian resection or hysterectomy within the last 12 months, and have heart disease (heart failure, angina pectoris, myocardial infarction)
  • Subjects that should be excluded from the commonly performed Cooperman test such as subjects, uncontrolled hypertensive subjects, malignant tumors, subjects with narrow angle glaucoma or lung disease, and subjects with severe renal or hepatic dysfunction, were excluded.
  • the study period was 8 weeks in total.
  • the total number of subjects was 60 (30 in each group), and the control group (6.5 g of fructooligosaccharide, 1 g of fructose, 0.4 g of red cabbage pigment, 0.5 g of citric acid, and 0.1 g of pomegranate flavor) and the experimental group according to the present invention.
  • Pomegranate extract elagic acid 1.8-3.2 mg / g).
  • the Cooperman Index which is commonly used to assess menopausal and menopausal symptoms.
  • the investigator directly evaluated the Cooperman index items for the symptoms, the intensity, the frequency, and the like of the symptom, and the score was written in the questionnaire, thereby containing the high content of ellagic acid of the present invention.
  • the effect of pomegranate extract was evaluated.
  • the pomegranate pulp extract containing the high content of ellagic acid according to the present invention was superior in improving the menopausal symptoms than the control group.
  • a pomegranate extract (sugar: 65 brix, ellagic acid: 0.80 to 1.40 mg / g) was prepared according to the method described in Korean Patent Registration No. 10-1272602, and as the experimental group, the same method as described in Example 3 above.
  • the Cooperman index was evaluated, except that 40ml / day pomegranate extract was ingested once a day.
  • the Cooperman index evaluated after taking the pomegranate extract according to Example 1 and the pomegranate extract of Korean Patent Registration No. 10-1272602 at the same time was confirmed to be similar, but the pomegranate extract according to Example 1 and the Korean Patent Registration Number Considering that the daily dose of pomegranate extract of No. 10-1272602 is 10 ml / day, the daily dose of pomegranate extract of Korean Patent No. 10-1272602 is 40 ml / day. It was found that the effect of improving menopausal symptoms can be achieved.
  • Example 3 when combining the results of Example 3 and Comparative Example 1 and Table 2 which is an evaluation result of the polyphenol content, the pomegranate extract of the present invention and pomegranate extract prepared according to Korean Patent No. 10-1272602 It contains a similar weight of polyphenols, the same level when the pomegranate extract 40ml / day prepared according to Korean Patent Registration No. 10-1272602 compared to the case of taking the present invention pomegranate extract 10ml / day within the same period In order to achieve the effect of improving menopausal symptoms, it was found that 4 times of polyphenols were taken together.
  • the pomegranate extract according to the present invention can achieve the equivalent effect even with a relatively small dose Therefore, the intake of polyphenols contained in pomegranate extract is also reduced to the contrary, it was confirmed that it is possible to take polyphenol-sensitive individuals.
  • the present invention relates to a health functional food for improving women's menopausal symptoms, containing a pomegranate extract as an active ingredient, containing 1.8 to 3.2 mg of ellagic acid per g of the total weight of the pomegranate extract.
  • the present invention contains 1.8 to 3.2 mg of ellagic acid per g of gross weight of pomegranate extract, and a maximum function of pomegranate extract per day of 15 ml or less, comprising a pomegranate extract as an active ingredient for improving female menopausal symptoms It is about food.
  • the dietary supplement is any one of 15ml, 14ml, 13ml, 12ml, 11ml, 10ml, 5ml, 4ml, 3ml, 2ml or 1ml pomegranate extract in a single dose. It is characterized in that the capacity of the fractional filling in an individual container.
  • the pomegranate is characterized in that the Turkish, American or a mixture thereof.
  • the health functional food is characterized in that the polyphenol component sensitive individuals can be taken.
  • the pomegranate extract is characterized in that the pomegranate flesh extract.
  • the present invention provides a process for preparing pomegranate extract containing 1.8-3.2 mg of ellagic acid per gram of total weight of pomegranate extract, comprising the following steps:
  • the pomegranate pulp decomposed product is sequentially heated and pressurized at least two times by heating and pressing at 70-100 ° C. and 400-850 mbar, and depressurizing at 40-80 ° C. and 100-350 mbar to heat-concentrate one or more times.
  • step S1 before the step S1, before the step S2, before the step S3, step S4, and after the step S4 characterized in that it further comprises the step of filtering.
  • the pomegranate extract is characterized in that the polyphenol component sensitive individuals can be taken.
  • step S4 is the first heating concentration at 400-550 mbar at 70-85 °C, the second heating concentration at 550-750 mbar at 85-92 °C, the third heating concentration at 750-850 mbar at 92-100 °C , 4 th heating concentration at 250-350 mbar at 60-80 ° C and 5 th heating concentration at 100-250 mbar at 40-60 ° C.
  • the present invention relates to a health functional food for improving women's menopausal symptoms comprising a pomegranate extract as an active ingredient, the maximum total daily dose of pomegranate extract prepared according to the above method to 15 ml or less.
  • the present invention relates to a pharmaceutical composition for improving menopausal symptoms comprising a pomegranate extract as an active ingredient, containing 1.8 to 3.2 mg of ellagic acid per g of the total weight of the pomegranate extract.
  • the present invention for improving female menopausal symptoms containing 1.8 to 3.2 mg of ellagic acid per g of the total weight of the pomegranate extract, the pomegranate extract daily maximum total dose of 15 ml or less, pomegranate extract as an active ingredient It relates to a pharmaceutical composition.
  • pomegranate extract per day can be expected to improve women's menopausal symptoms, and therefore, polyphenol-sensitive individuals can be administered.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne un extrait de grenade et une composition contenant celui-ci, 1,8 à 3,2 mg d'acide ellagique en faisant partie en fonction d'une unité par gramme du poids total de l'extrait de grenade, ce qui présente ainsi un excellent effet de soulagement de symptômes de la ménopause chez la femme, même avec une petite quantité d'administration quotidienne de l'extrait de grenade. En outre, selon la présente invention, il y a l'avantage de permettre l'administration de l'extrait à un individu sensible à un polyphénol.
PCT/KR2015/009464 2015-01-14 2015-09-08 Extrait de grenade permettant de soulager les symptômes de la ménopause chez la femme, contenant une teneur élevée d'acide ellagique WO2016114470A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2017537301A JP6694888B2 (ja) 2015-01-14 2015-09-08 高含量のエラグ酸を含む女性更年期症状改善用ザクロ抽出物
EP15878114.6A EP3246040B1 (fr) 2015-01-14 2015-09-08 Extrait de grenade permettant de soulager les symptômes de la ménopause chez la femme, contenant une teneur élevée d'acide ellagique
CN201510702482.XA CN106491667B (zh) 2015-01-14 2015-10-26 用于缓解妇女的绝经期症状的具有高含量鞣花酸的石榴提取物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/596,778 2015-01-14
US14/596,778 US9839659B2 (en) 2012-10-02 2015-01-14 Pomegranate extract containing large amount of ellagic acid and use of the pomegranate extract

Publications (1)

Publication Number Publication Date
WO2016114470A1 true WO2016114470A1 (fr) 2016-07-21

Family

ID=56405995

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/009464 WO2016114470A1 (fr) 2015-01-14 2015-09-08 Extrait de grenade permettant de soulager les symptômes de la ménopause chez la femme, contenant une teneur élevée d'acide ellagique

Country Status (4)

Country Link
EP (1) EP3246040B1 (fr)
JP (1) JP6694888B2 (fr)
CN (1) CN106491667B (fr)
WO (1) WO2016114470A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160011536A (ko) * 2014-07-22 2016-02-01 (주) 건강사랑 석류 농축물을 유효성분으로 포함하는 피부 개선용 조성물
WO2021106857A1 (fr) * 2019-11-29 2021-06-03 小林製薬株式会社 Composition prévenant ou atténuant l'angoisse liée à l'envie d'uriner, et composition pour amélioration du sommeil
JPWO2021106856A1 (fr) * 2019-11-29 2021-06-03

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110113122A (ko) * 2010-04-08 2011-10-14 이해련 고함량의 엘라그산을 포함하는 석류 추출물, 및 석류 추출물의 갱년기 증상 관련 효과를 향상시키는 방법
US20150125556A1 (en) * 2012-10-02 2015-05-07 Hae-Yeon LEE Pomegranate extract containing large amount of ellagic acid and use of the pomegranate extract
KR20150115502A (ko) * 2014-04-04 2015-10-14 (주) 건강사랑 고함량의 엘라그산을 포함하는 여성 갱년기 증상 개선용 석류 추출물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986749B2 (en) * 2010-04-08 2015-03-24 Hae-Yeon LEE Pomegranate extract having a high ellagic acid content, and use of the pomegranate extract
WO2011126324A2 (fr) * 2010-04-08 2011-10-13 주식회사 건강사랑 Extrait de grenade ayant une teneur élevée en acide ellagique et utilisation de l'extrait de grenade

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110113122A (ko) * 2010-04-08 2011-10-14 이해련 고함량의 엘라그산을 포함하는 석류 추출물, 및 석류 추출물의 갱년기 증상 관련 효과를 향상시키는 방법
US20150125556A1 (en) * 2012-10-02 2015-05-07 Hae-Yeon LEE Pomegranate extract containing large amount of ellagic acid and use of the pomegranate extract
KR20150115502A (ko) * 2014-04-04 2015-10-14 (주) 건강사랑 고함량의 엘라그산을 포함하는 여성 갱년기 증상 개선용 석류 추출물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM, H. H. ET AL.: "Estrogenic Activity and Physiological Active Components of Iranian Black Pomegranate Seed Extracts", INDUSTRIAL FOOD ENGINEERING, vol. 11, no. 4, 2007, pages 305 - 312, XP009504423 *
MORI-OKAMOTO, JUNKO ET AL.: "Pomegranate Extract improves a Depressive State and Bone Properties in Menopausal Syndrome Model Ovariectomized Mice", JOURNAL OF ETHNOPHARMACOLOGY, vol. 92, no. 1, May 2004 (2004-05-01), pages 93 - 101, XP002497183 *
See also references of EP3246040A4 *

Also Published As

Publication number Publication date
JP2018503378A (ja) 2018-02-08
EP3246040B1 (fr) 2020-11-11
CN106491667B (zh) 2020-09-18
JP6694888B2 (ja) 2020-05-20
EP3246040A1 (fr) 2017-11-22
CN106491667A (zh) 2017-03-15
EP3246040A4 (fr) 2018-08-22

Similar Documents

Publication Publication Date Title
KR101272602B1 (ko) 고함량의 엘라그산을 포함하는 석류 추출물, 및 석류 추출물의 갱년기 증상 관련 효과를 향상시키는 방법
US8986749B2 (en) Pomegranate extract having a high ellagic acid content, and use of the pomegranate extract
KR20080104600A (ko) 인삼 열매 추출물을 함유하는 혈행촉진, 혈관신생촉진, 및허혈성 심질환 치료용 조성물
WO2016114470A1 (fr) Extrait de grenade permettant de soulager les symptômes de la ménopause chez la femme, contenant une teneur élevée d'acide ellagique
CN108463231B (zh) 含有黃漆木提取物作为有效成分的更年期疾病的预防及治疗用组合物
WO2014200234A1 (fr) Composition contenant un extrait composite de rehmannia glutinosa et de pueraria lobata destinée à prévenir ou à traiter des symptômes de la ménopause
KR102014208B1 (ko) 고함량의 엘라그산을 포함하는 여성 갱년기 증상 개선용 석류 추출물
KR101850130B1 (ko) 고함량의 엘라그산을 포함하는 여성 갱년기 증상 개선용 석류 추출물
US9839659B2 (en) Pomegranate extract containing large amount of ellagic acid and use of the pomegranate extract
KR100542478B1 (ko) 석류 유래 피토에스트로겐을 함유하는 건강기능식품
WO2011126324A2 (fr) Extrait de grenade ayant une teneur élevée en acide ellagique et utilisation de l'extrait de grenade
KR100769412B1 (ko) Ｐｒ-119 복합생약 추출물을 함유하는 전립선 비대증의예방 및 치료용조성물
KR20120137335A (ko) 고함량의 엘라그산을 포함하는 석류 추출물, 및 석류 추출물의 갱년기 증상 관련 효과를 향상시키는 방법
Ibekwe Effect of methanolic crude extract of Aframomum melegueta (Am) seeds on selected lactogenic hormones of Albino rats
KR101822442B1 (ko) 의이인 및 인진 추출물을 유효성분으로 함유하는 성조숙증의 예방, 개선 또는 치료용 조성물
KR100542479B1 (ko) 석류 유래 피토에스트로겐을 함유하는 호르몬 대체 요법용피토에스트로겐 조성물
WO2021066431A1 (fr) Vésicules extracellulaires dérivées de la grenade et leur utilisation
CN114522190B (zh) 一种抗心肌缺血损伤的药物组合物及其制备方法和应用
KR20110089036A (ko) 불임증 개선을 위한 기능성 식품조성물
KR100505746B1 (ko) 석류씨 유래 피토에스트로겐 함유 건강기능식품의 제조방법
KR100522565B1 (ko) 석류 유래 피토에스트로겐을 함유하는 건강기능식품의제조방법
CN118104819A (zh) 一种用于卵巢保健的组合物及其制备方法和应用
KR970011293B1 (ko) 귀룡원 약제의 제조방법
KR100474110B1 (ko) 피부 탄력 및 윤택 증강용 푸에라리아 미리피카 유래의 추출물
CN109152729B (zh) 用于治疗pcos(多囊卵巢综合征)的单味草药提取物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15878114

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017537301

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015878114

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE